These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25617259)

  • 21. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis.
    Oliveira B; Arkfeld DG; Weitz IC; Shinada S; Ehresmann G
    J Clin Rheumatol; 2007 Apr; 13(2):89-91. PubMed ID: 17414538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
    Downey C
    Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Case Report; Long-term treatment with etanercept induced systemic sarcoidosis in a patient with rheumatoid arthritis].
    Yokoe I; Haraoka H; Yonamine T; Sato R; Nishiwaki A; Takei M
    Nihon Naika Gakkai Zasshi; 2015 Apr; 104(4):769-74. PubMed ID: 26536740
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
    Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
    Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
    Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
    Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents.
    Tanaka M; Sakai R; Koike R; Harigai M
    J Rheumatol; 2015 Sep; 42(9):1726-8. PubMed ID: 26330129
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis.
    Chen M; Peng D; Zhang Z; Zuo G; Zhao G
    Int J Rheum Dis; 2016 Nov; 19(11):1132-1142. PubMed ID: 26354025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
    Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
    Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rheumatoid arthritis and ocular myasthenia gravis: Effectiveness of rituximab in the management of these two diseases.
    Novella-Navarro M; Salvatierra-Ossorio J; Muñoz-Gómez MDM; Pavo-Blanco M
    Reumatol Clin (Engl Ed); 2018; 14(3):179-180. PubMed ID: 28624374
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept.
    Rákóczi É; Perge B; Végh E; Csomor P; Pusztai A; Szamosi S; Bodnár N; Szántó S; Szücs G; Szekanecz Z
    Joint Bone Spine; 2016 Dec; 83(6):675-679. PubMed ID: 26995488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
    Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
    Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Counterintuitive Pulmonary Nodules in Rheumatoid Arthritis.
    Zamora FD; Podgaetz E; Dincer HE
    Arch Bronconeumol; 2016 Jun; 52(6):334-5. PubMed ID: 26818558
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.